"The FDA will approve vaccines for high-risk persons and, at the same time, demand robust, gold-standard data on persons at low risk," the agency said in an article published by The New England Journal of Medicine, authored by FDA Commissioner Dr. Martin Makary and his new top vaccines official, Dr. Vinay Prasad.

Only adults 65 and older or people with another health problem that puts them at higher risk will be able to get the shots under the FDA's new framework.

The new framework was well-received by biopharma analysts, who say it “largely formalizes” current COVID-19 vaccination trends.

JPMorgan analyst Eric Joseph reaffirmed an Underweight rating for Novavax Inc. (NASDAQ:NVAX) with a price target of $7. This comes after the Food and Drug Administration (FDA) approved the company’s COVID-19 vaccine,

Health-related headlines include Mexico's suspension of poultry imports from Brazil due to bird flu, promising results from new HIV vaccine trials, and the FDA's conditional approval of Novavax's COVID-19 vaccine.

Coinbase Global (COIN) will begin trading on the S&P 500 (^GSPC) effective today, replacing Discover Financial Services (DFS) on the exchange. The US Food and Drug Administration (FDA) approves Novavax's (NVAX) COVID-19 vaccine,